Clinical trials: COVID-19 Booster
COVID-19
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
This is an experimental study without drug and device, non-profit, single-center. The general objective of the project is to study how the adaptive immune response evolves against SARS-CoV-2 with repeated vaccination boosters and…
- Trial name
- COVaxFragile (NCT06300853)
- Testing
- Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses
- Where
- Italy
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
COVID-19
Puerto Rico COVID-19 Vaccine Uptake Study
The purpose of this study is to recruit a total of 386 participants to evaluate the effectiveness of an educational program to increase the proportion of men and women aged 21 years and older who have received the COVID-19…
- Trial name
- PR-COVACUPS (NCT05468021)
- Testing
- Educational intervention
- Where
- 2 sites in Puerto Rico
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- University of Puerto Rico
COVID-19, SARS-CoV-2 Infection
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
A observer-blind, randomized, controlled, investigator-initiated clinical trial to evaluate the safety and immunogenicity of a booster vaccination with Recombinant COVID-19 vaccine (Sf9 Cell) in a population aged 18-60 years old…
- Trial name
- NCT06381843
- Testing
- Recombinant COVID-19 Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
Open-label, prospective intervention study of IndoVac® as a single, homologous booster dose
- Trial name
- NCT05933278
- Testing
- SARS-CoV-2 Subunit Recombinant Protein Vaccine
- Where
- Indonesia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
COVID-19 Pandemic
A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5
It is a single center, randomized, open-labeled, exploratory clinical study to evaluate the safety and immunogenicity of Recombinant SARS-CoV-2 Fusion Protein bivalent Vaccine V-01-B5 as a second booster in adults aged 18-59…
- Trial name
- COVID-19 (NCT05585567)
- Testing
- V-01/V-01-B5, V-01-351/V-01-B5, V-01
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198102
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Vaccine Response, COVID-19 Vaccine
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine.
- Conditions
- Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination
- Trial name
- NCT06821100
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
COVID-19, Vaccine Reaction
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose…
- Trial name
- NCT05928455
- Testing
- LYB001, CoronaVac
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
SARS-CoV2, COVID-19
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended…
- Trial name
- NCT06672055
- Testing
- VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
- Where
- 145 sites in United States
- Volunteers
- 5,485 people
- Sponsor
- Vaxart
COVID-19
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
This is a multicenter, randomized, observer-blinded, active-controlled Phase II study to evaluate the immunogenicity, safety and reactogenicity of the low dose (20μg) and high dose (40μg) of ReCOV, when administered as a booster…
- Trial name
- NCT05323435
- Testing
- Recombinant two-component COVID-19 vaccine (CHO cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
COVID-19, Vaccine Reaction
A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine
This project is a prospective observational real-world study, recruiting and screening subjects who have completed 2 doses of the COVID-19 vaccine for more than 6 months and receive the third dose of the vaccine voluntarily into…
- Trial name
- NCT05493917
- Testing
- an inactivated SARS-CoV-2 vaccine named BBIBP-CorV
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Kidney Diseases, Kidney Transplant; Complications
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in…
- Conditions
- Kidney Diseases, Kidney Transplant; Complications, COVID-19, Vaccine Adverse Reaction
- Trial name
- NCT05483725
- Testing
- Booster dose of mRNA vaccine
- Where
- Czechia
- Volunteers
- 108 people
- Sponsor
- Institute for Clinical and Experimental Medicine
COVID-19 Vaccine
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
The purpose of this study is to assess the safety, tolerability, and immunogenicity of booster dose of vaccine in participants who are generally healthy or with stable pre-existing health conditions.
- Trial name
- NCT05197153
- Testing
- Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222
- Where
- 4 sites in Taiwan
- Volunteers
- 804 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
COVID-19
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED).
- Trial name
- PROBOOSTVAXED (NCT06156215)
- Testing
- Vaccine Messaging, Vaccine Acceptance Question
- Where
- 7 sites in United States
- Volunteers
- 919 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Anti-SARS-CoV-2 Antibody Response
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines
The investigators aim to evaluate the ability of a COVID-19 (Coronavirus disease) booster vaccine to induce a salivary antibody response and investigate a possible correlation with the serum antibody response and the cellular…
- Trial name
- CoVVacBoost (NCT05142540)
- Testing
- blood and saliva samples will be taken
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
COVID-19
Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination
Data from some studies indicate the decline in the effectiveness of the authorized COVID-19 vaccines due to antibody waning following vaccination and the emergence of different variants.
- Trial name
- NCT05545683
- Testing
- VLA 2001
- Where
- Colombia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centro de Estudios en Infectogía Pediatrica
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
This is an observer blind randomized controlled trial study to evaluate the humoral immunogenicity profile - neutralizing antibody - after 28 days following vaccination with Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell…
- Trial name
- NCT05918939
- Testing
- Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg, CoronaVac Biofarma COVID-1 9 Vaccine 3 µg
- Where
- Indonesia
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Kidney Transplant Recipient
Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients
The purpose of this research is to see if a dose of the Janssen Ad26.CoV2.S vaccine effects the immune protection in individuals who have had a kidney transplant and two or three doses of mRNA vaccine (Pfizer and/or Moderna…
- Trial name
- NCT05220397
- Testing
- Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
- Where
- 3 sites in United States
- Volunteers
- 468 people
- Sponsor
- Mark Stegall
COVID-19
Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).
This is a single-blind, randomised controlled clinical trial to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccines (Pfizer-BioNTech or Moderna) as booster dose…
- Trial name
- MIACoV (NCT05228730)
- Testing
- Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose
- Where
- Australia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute